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Introduction
Colorectal cancer (CRC) screening programs, including fecal 
occult blood testing and colonoscopy, have proven to be effective 
in reducing CRC incidence for people aged 50 years and older 
in the US but the protection is incomplete.1-3 A particular cause 
for concern is evidence of increasing trends in CRC incidence at 
younger ages.4 An increase in the younger segment of the popula-
tion is unlikely to be arrested by current screening programs, as 
individuals younger than age 50 are not routinely tested unless 
they are symptomatic or have a family history of CRC. Therefore, 
reliable markers of CRC risk would be important to develop 
changes in the methylation levels of DNa from white blood cells (WBcs) are putatively associated with an elevated 
risk for several cancers. The aim of this study was to investigate the association between colorectal cancer (cRc) and 
the methylation status of three DNa repetitive elements in DNa from peripheral blood. WBc DNa from 539 cRc cases 
diagnosed before 60 years of age and 242 sex and age frequency-matched healthy controls from the australasian 
colorectal cancer Family Registry were assessed for methylation across DNa repetitive elements alu, LINE-1 and sat2 
using MethyLight. The percentage of methylated reference (pMR) of cases and controls was calculated for each marker. 
Odds ratios (ORs) and 95% confidence intervals (cIs) were estimated using multivariable logistic regression adjusted for 
potential confounders. cRc cases demonstrated a significantly higher median pMR for LINE-1 (p < 0.001), sat2 (p < 0.001) 
and alu repeats (p = 0.02) when compared with controls. For each of the DNa repetitive elements, individuals with pMR 
values in the highest quartile were significantly more likely to have cRc compared with those in the lowest quartile (LINE-
1 OR = 2.34, 95% cI = 1.48–3.70; p < 0.001, alu OR = 1.83, 95% cI = 1.17–2.86; p = 0.01, sat2 OR = 1.72, 95% cI = 1.10–2.71; 
p = 0.02). When comparing the OR for the pMR of each marker across subgroups of cRc, only the alu marker showed a 
significant difference in the 5-fluoruracil treated and nodal involvement subgroups (both p = 0.002). This association 
between increasing methylation levels of three DNa repetitive elements in WBc DNa and early-onset cRc is novel and 
may represent a potential epigenetic biomarker for early cRc detection.
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targeted screening and consequently lead to further reductions in 
CRC related morbidity and mortality.
The measurement of DNA methylation levels from white blood 
cells (WBCs) has recently been investigated as a method of iden-
tifying cancer-affected individuals or those who are at a higher 
risk of cancer.5 Previous studies have shown that both hypo- and 
hyper-methylation of DNA from WBCs is associated with sev-
eral different types of neoplasia, including bladder, breast, renal, 
and head and neck cancer.6-9 However, the association between 
methylation levels of DNA from leukocytes and the risk of CRC 
has not been well investigated. The measurement of methylation 
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The aim of this study was to investigate associations between 
the DNA methylation levels of three repetitive DNA elements, 
LINE-1, Alu and Sat2, in peripheral blood leukocytes and hav-
ing CRC.
Results
The characteristics of the participants in this study compris-
ing 539 cases diagnosed with CRC between the ages of 18 and 
59 years (54.4% male) and 242 healthy controls (52.9% male) 
are listed in Table 1. The MethyLight inter-assay coefficients of 
variation (CV) for the Alu, LINE-1 and Sat2 markers were 0.52, 
0.37 and 0.30, respectively. There was no significant difference 
in the mean or median age at diagnosis of the cases [mean age 
at diagnosis ± standard deviation (SD) = 48.8 ± 7.6 y; median = 
50.0 y], when compared with the mean and median age at inter-
view/blood draw for controls (49.0 ± 8.5 y; p = 0.74; median = 
50.0 y, p = 0.37) (Table 1). The median time elapsed between age 
at diagnosis and blood draw for cases was 1 year, ranging from 
blood drawn at the time of diagnosis up to 14 years after diagno-
sis, where 92% of the CRC cases had their blood drawn within 
2 years after CRC diagnosis. The median age of blood draw for 
the controls was 2 years younger than the median age of blood 
draw for the CRC cases (p = 0.03). Cases had a higher BMI and 
were less likely to use ibuprofen than controls (p ≤ 0.001 and 
p = 0.02, respectively); cases also reported a stronger family his-
tory of CRC than controls (Table 1).
Cases demonstrated significantly higher median PMR val-
ues across each of the three repetitive elements compared with 
controls (Alu, p = 0.02; LINE-1, p ≤ 0.001; Sat2, p ≤ 0.001; 
Table 1). When individuals were grouped into quartiles based 
on the PMR distribution for the controls, the highest levels of 
methylation (Q4) for each of the repetitive elements were sig-
nificantly associated with higher odds of CRC compared with 
the lowest quartile (Table 2). The association was strongest for 
the LINE-1 repetitive element (OR = 2.34, 95% CI = 1.48–3.70, 
p < 0.001) followed by Alu (OR = 1.83, 95% CI = 1.17–2.86, 
p = 0.01) and Sat2 (OR = 1.72, 95% CI = 1.10–2.71, p = 0.02). 
For the LINE-1 and Sat2 DNA repetitive elements, higher odds 
of being CRC-affected were also observed for PMR values in 
the third quartile compared with the lowest (OR = 1.71, 95% 
CI = 1.07–2.71, p = 0.02; OR = 1.81, 95% CI = 1.14–2.85, 
p = 0.01, respectively; Table 2). For each of the DNA repetitive 
elements, a statistically significant increasing linear trend in ORs 
was observed from Q1 to Q4 (Alu p
trend





 = 0.002; Table 2). There was evidence for a log-
linear trend for LINE-1 and Sat2 when the PMR were analyzed 
as a continuous variable (p < 0.001 and p = 0.001, respectively), 
although less so for the Alu marker (p = 0.04). Similar effects 
were observed for each of the DNA repetitive elements when the 
analysis was restricted to CRC-affected cases that had their blood 
taken within 1 year of their diagnosis (n = 292, 54% of cases; 
Table S1).
The number of DNA repetitive elements with methylation lev-
els (PMR values) in the highest quartile was also associated with 
a higher prevalence of CRC (Table 3). Results are presented for 
with global methylation levels,10 due to the fact they are well inter-
spersed throughout the genome, comprising approximately 45% of 
the total DNA sequence.11 A number of different classes of repeti-
tive elements including Alu [a short interspersed nucleotide element 
(SINE) that is the most abundant repeat in the human genome12], 
LINE-1 (a long interspersed nucleotide element (LINE) comprising 
approximately 17% of the human genome13), and Satellite 2 (Sat2) 
(a short tandem repeat), have all been previously shown to demon-
strate significantly different methylation levels in DNA from WBCs 
of cancer-affected cases compared with unaffected controls.7,14-16
Table 1. characteristics of cRc-affected cases and healthy controls
Characteristic Controls Cases p-value
(n = 242) (n = 539)
Demographic data Freq % Freq %




50 (43, 56) 50 (43, 55) 0.37
at blood draw* 50 (43, 56) 52 (45, 57) 0.03
caucasian 231 95.5% 512 95% 0.78
smoking status
Never 110 45.5% 249 46.2% 0.70
Former 87 36% 179 33.2%
current 45 18.6% 111 20.6%
Drinking status
Never 32 13.2% 107 19.9% 0.08
Former 21 8.7% 43 8%
current 189 78.1% 387 72.1%
Body mass index 
(kg/m2)*
25.1 (22.4, 28.4) 26.5 (23.5, 29.7) < 0.001
Medicines/ 
supplements
2 years ago, taking
Folic acid 8 3.3% 12 2.3% 0.39
aspirin 14 5.8% 25 4.6% 0.50
Ibuprofen 11 4.5% 21 3.9% 0.69
have you ever taken
Folic acid 39 16.2% 67 12.5% 0.17
aspirin 30 12.4% 59 11% 0.56
Ibuprofen 50 20.7% 76 14.2% 0.02
Family history
FDRΔ with cRc 45 18.6% 130 24.1% 0.09
FDR/sDR† with cRc 80 33.1% 249 46.2% 0.001
Repetitive  
DNA elements
alu pMR* 70 (46, 94) 75 (50, 110) 0.02
LINE-1 pMR* 72 (48, 107) 87 (59, 130) < 0.001
sat2 pMR* 66 (49, 96) 80 (57, 111) < 0.001
*Figures shown are median (Q1, Q3). Δ FDR, first degree relative; †sDR, 
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between hypomethylation in both colonic mucosa and leukocyte 
DNA and an increased risk for colorectal adenomas and a non-
significant increased risk for CRC in 35 and 28 patients, respec-
tively. Lim et al.18 also described an association between global 
DNA hypomethylation and an increased risk for colorectal ade-
nomas in the peripheral blood DNA of 115 women. In contrast, 
Nan et al.,19 found no association between overall WBC DNA 
methylation level and CRC risk among 358 female CRC cases 
where blood samples had been collected prior to CRC diagnosis. 
More recent studies have focused on measuring DNA repetitive 
elements as surrogate markers for global DNA methylation levels. 
Kitkumthorn et al.20 demonstrated significantly lower LINE-1 
DNA methylation in the WBCs of 36 CRC-affected cases com-
pared with controls. In a prospective study of WBC DNA meth-
ylation and cancer risk, including CRC, Zhu et al.14 demonstrated 
a 3-fold increased incidence of all cancers in individuals with low 
LINE-1 methylation levels. No significant association however 
was observed between WBC DNA methylation and CRC, either 
at baseline or longitudinal CRC development, based on only 23 
and 3 CRC cases, respectively.
A recent review by Brennan and Flanagan21 has discussed some 
of the limitations of these previous studies regarding the reported 
associations between WBC DNA methylation and cancer risk. 
Differences in study design (retrospective vs. prospective), meth-
ylation testing methodology as well as the case and control 
each category, since the likelihood ratio test provided some evi-
dence against a linear trend across categories (p = 0.06). Having 
three DNA repetitive elements with PMR values in the highest 
quartile nearly tripled the odds of being diagnosed with CRC 
compared with individuals with no DNA repetitive elements 
with methylation levels (PMR values) in the highest quartile (OR 
= 2.96, 95% CI = 1.56–5.59, p = 0.001).
When cases were placed into subgroups according to age at 
diagnosis, tumor characteristics ]site, node status, T-stage, BRAF 
p.V600E mutation, mismatch repair (MMR)-status], chemo-
therapy treatment, germline mutation status (MMR gene or 
MUTYH mutations), and family history of CRC, we observed 
no significant difference in the association between PMR lev-
els and CRC across subgroups (Table 4), other than for lymph 
node involvement and 5FU treatment subgroups, where the ORs 
were significantly different for the Alu repetitive element only 
(p = 0.002 for both).
Discussion
In this study, we observed a strong association between increased 
methylation levels of DNA repetitive elements Alu, LINE-1 and 
Sat2 in peripheral blood WBC DNA and CRC. This association 
did not depend on age, sex, BMI, family history, tumor stage, 
smoking status, alcohol intake, ethnicity, medication and supple-
ment usage, or chemotherapeutic treatment. These findings sug-
gest that increased DNA methylation in WBCs may represent a 
biomarker of CRC predisposition. Assessing WBC DNA meth-
ylation has the potential to be a highly cost-effective and tissue 
accessible approach to population screening in order to identify 
individuals at greater risk of developing CRC, improve early 
detection rates and ultimately reduce the incidence of CRC within 
the population, particularly for those individuals under age 50 
who would normally not be screened for CRC and a group in 
which the incidence of CRC may be increasing.
Several previous studies have investigated the association 
between WBC global DNA methylation levels and neoplasia in 
the colorectum. Pufulete and colleagues17 reported an association 
Table 2. pMR values of cRc-affected cases analyzed as quartiles* (Q1 lowest, Q4 highest) and as a continuous variable* (OR per unit increase of logged 
pMR value) for each repetitive DNa element
PMR quartile Q1 Q2 Q3 Q4 Test for trend PMR continuous
sat2
p 0.31 0.01 0.02 0.002 0.001
95% cI (0.48, 1.26) (1.14, 2.85) (1.10, 2.71) (1.22, 2.25)
OR Ref 0.78 1.81 1.72 1.66
LINE-1
p 0.34 0.02 < 0.001 < 0.001 < 0.001
95% cI (0.78, 2.06) (1.07, 2.71) (1.48, 3.70) (1.25, 2.05)
OR Ref 1.27 1.71 2.34 1.6
alu
p 0.59 0.84 0.01 0.005 0.04
95% cI (0.72, 1.79) (0.66, 1.66) (1.17, 2.86) (1.01, 1.70)
OR Ref 1.13 1.05 1.83 1.31
*Models adjusted for age at blood draw (continuous), sex, body mass index (quartiles), smoking status, drinking status, ethnicity (caucasian/not), and 
binary use of folate, aspirin and ibuprofen two years ago, and family history (FDR or sDR) of cRc.
Table 3. combined effect of hypermethylation over multiple repetitive 
elements
Number of markers in highest 
quartile:
OR 95% CI P
0 Ref
1 1.99 (1.35, 2.94) < 0.001
2 1.63 (1.04, 2.56) 0.03
3 2.96 (1.56, 5.59) 0.001
LRT test* 0.06
*LRT, likelihood ratio test: compares the categorical pMR variable with 
























younger than the CRC-affected cases without mention of statisti-
cal adjustment for this age difference. The age at which blood is 
drawn from cases and controls is an important consideration since 
previous studies have shown that global de-methylation can occur 
with increasing age.22,23 Therefore, we studied cases and controls 
matched for ethnicity, age and sex frequency in order to minimize 
any age-related effects on methylation levels. As a result, our find-
ings may be more relevant for early-onset CRC risk rather than 
related to CRC risk overall, where the majority of CRC cases in 
the population are diagnosed over the age of 60 years.
Another potential explanation for the discrepancy between 
study findings is the different methodologies used for testing 
characteristics, including ethnicity, gender and mean age at diag-
nosis/blood draw, are likely to explain some of the differences in 
findings between previous studies of colorectal neoplasia and the 
present study. For example, Kitkumthorn et al.,20 studied an Asian 
population of CRC-affected cases and controls compared with 
our study of predominantly Caucasian CRC-affected cases and 
controls. Across the previous studies described above, the mean 
age at diagnosis of colorectal neoplasia ranged from 60 to 74 years, 
which contrasts the median age at CRC diagnosis of the cases 
in this study (50 years). Furthermore, a potential confounder of 
the findings of two previous studies17,20 was the difference in the 
age of the controls, which on average, were more than 10 years 
Table 4. comparison of the association between pMR values (on the logarithm scale) and cRc risk between subgroups
Subgroup Cases Alu LINE-1 Sat2
n OR 95% CI P* OR 95% CI P* OR 95% CI P*
5FU**
No 5FU 173 2.01 (1.41, 2.84) 0.002 1.83 (1.33, 2.53) 0.33 1.91 (1.28, 2.85) 0.68
5FU 196 1.14 (0.81, 1.60) 1.56 (1.15, 2.11) 1.76 (1.20, 2.58)
BRAF
Negative 452 1.38 (1.05, 1.80) 0.41 1.64 (1.27, 2.12) 0.59 1.78 (1.29, 2.44) 0.09
positive 31 1.08 (0.59, 1.97) 1.4 (0.79, 2.50) 0.98 (0.48, 2.00)
MMR†
proficient 451 1.41 (1.08, 1.85) 0.23 1.66 (1.29, 2.15) 0.3 1.73 (1.26, 2.38) 0.78
Deficient 39 1.01 (0.57, 1.78) 1.27 (0.75, 2.15) 1.59 (0.84, 3.00)
Nodes
No positive 224 1.68 (1.25, 2.28) 0.002 1.73 (1.30, 2.30) 0.44 1.87 (1.32, 2.66) 0.24
positive 204 1.05 (0.76, 1.45) 1.54 (1.14, 2.08) 1.52 (1.05, 2.20)
T-stage
T1/T2 219 1.32 (0.97, 1.79) 0.96 1.47 (1.09, 1.97) 0.29 1.66 (1.16, 2.38) 0.99
T3/T4 320 1.31 (0.98, 1.73) 1.7 (1.29, 2.24) 1.66 (1.19, 2.31)
Age at
diagnosis
< 40 y 76 1.37 (0.89, 2.10) 0.35 1.98 (1.30, 3.00) 0.31 1.66 (1.01, 2.73) 0.75
40–< 50 y 170 1.12 (0.80, 1.56) 1.42 (1.03, 1.95) 1.81 (1.23, 2.67)
50–59 y 293 1.41 (1.06, 1.88) 1.62 (1.23, 2.14) 1.58 (1.13, 2.20)
Site
Rectum 189 1.35 (0.97, 1.86) 0.08 1.58 (1.16, 2.15) 0.35 1.88 (1.29, 2.76) 0.81
Left colon 148 1.71 (1.20, 2.42) 1.9 (1.36, 2.66) 1.66 (1.10, 2.49)
Right colon 126 1.09 (0.76, 1.57) 1.46 (1.04, 2.05) 1.7 (1.11, 2.60)
Germline Mutation
None Found 492 1.37 (1.05, 1.78) 0.07 1.63 (1.26, 2.10) 0.69 1.66 (1.22, 2.26) 0.96
MMR† 37 1.04 (0.58, 1.87) 1.46 (0.84, 2.53) 1.78 (0.94, 3.38)
MUTYH 10 0.46 (0.17, 1.26) 1.09 (0.41, 2.90) 1.51 (0.46, 4.97)
Family History
None 40 1.18 (0.68, 2.04) 0.83 1.53 (0.91, 2.59) 0.97 2.01 (1.07, 3.76) 0.57
FDRΔ cRc 130 1.26 (0.88, 1.80) 1.64 (1.16, 2.32) 1.74 (1.14, 2.65)
FDRΔ polypectomy 356 1.35 (1.02, 1.78) 1.6 (1.23, 2.08) 1.52 (1.10, 2.10)
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treatment is unlikely to be the reason for the association with 
DNA hypermethylation and CRC risk we observed. In addition 
to chemotherapy, other exogenous or environmental factors may 
influence DNA methylation.5 In this study, we adjusted for and 
observed no evidence of association with potential confound-
ers of DNA methylation including cigarette smoking, drinking 
alcohol, BMI, use of NSAIDs and folate intake. Despite this, we 
cannot exclude the possibility that other unmeasured factors have 
contributed to the differences in methylation levels between cases 
and controls, as has been previously reported including MTHFR 
polymorphism33 (altering folate metabolism), phytoestrogen 
intake,34 arsenic exposure35 and amount of physical activity.36
The strengths of this study include the large sample size of cases 
from a population-based resource, use of sex and age matched 
controls, and statistical analysis adjusting for multiple potential 
confounding factors including 5FU chemotherapy. Protocols for 
blood collection, processing and DNA extraction were consistent 
between cases and controls. When considering the limitations of 
this study, the time of blood draw for cases was after the diag-
nosis of CRC, which makes it unclear as to whether the DNA 
hypermethylation predisposes to CRC development (cause), or 
is related to metabolic changes caused by cancer growth or treat-
ment (consequence). To further address this question of cause or 
consequence, prospective cohort studies will be needed to iden-
tify and quantify the risk, if any, between differences in periph-
eral blood methylation and cancer risk. Another consideration is 
that the DNA extracted from our participants was from whole 
blood. There can be differences in the cell count of a particular 
type of circulating WBC, with a recent study showing differ-
ent DNA methylation levels between different WBC cell types.37 
Therefore, an individual’s methylation profile may be dependent 
upon their composition of WBCs.5 Inflammation is one bio-
logical response which can cause a shift in the distribution of 
particular WBC types, for example after surgery or during an 
infection.38
In summary, this study is the first to identify an association 
between the association of CRC and increased levels of methyla-
tion in three repetitive DNA elements in WBC DNA. Further 
studies are needed using prospective cohort designs in order to 
confirm this finding, further elucidate a cause or consequence 
association and to provide further evidence for the utility of 
measuring methylation levels within WBC DNA as a potential 
biomarker of CRC. Assessing the methylation levels of repeti-
tive DNA elements from a routine blood sample is an attractive 
prospect for identifying individuals with early stage CRC, or pos-
sibly those at a higher risk of developing CRC, and therefore, 
has important health and economic benefits. Furthermore, an 
individual’s WBC methylation level could be used in conjunc-
tion with other known CRC risk factors in risk prediction mod-
eling to ultimately determine an accurate personalized CRC risk 
prediction.
Methods
Study participants. Incident CRC cases (n = 618) diagnosed 
before 60 years of age (45.6% diagnosed less than 50 years of 
methylation levels, each with their own limitations (discussed in 
Brennan and Flanagan, 2012).21 Currently, sequencing of bisul-
phite converted DNA is considered the “gold standard” for DNA 
methylation analysis, however, this is a low-throughput method. 
More recent studies have utilized pyrosequencing to measure 
DNA repetitive element methylation; however, this approach 
only captures a small region of an otherwise large repeat, measur-
ing only 4 CpGs between nucleotide 318–331 within the LINE-1 
5' UTR.24 In this study, we have utilized MethyLight, a methyla-
tion specific PCR-based assay that captures methylation across 
10 CpGs between nucleotide 251 and 331 of the LINE-1 
5' UTR.10 When considering our findings we have shown hyper-
methylation of not just the LINE-1 repetitive element but for all 
three of the repetitive DNA elements tested, adding support to 
the concept that methylation levels throughout the genome may 
be altered. Replication of these and other study findings using the 
same methodology is needed.
Consistent with our findings of increased WBC DNA meth-
ylation being associated with CRC, a recent study demonstrated 
a significant increase in WBC DNA methylation levels for breast 
cancer cases compared with controls using the LUMA assay, 
however, no specific association with LINE-1 methylation was 
observed.25 In addition, a study by Liao et al.,7 on 328 renal cell 
carcinoma patients demonstrated an association between LINE-1 
hypermethylation of WBC DNA and an increased risk of renal 
cell carcinoma. This suggests that peripheral blood DNA hyper-
methylation may be a marker of predisposition not only for CRC, 
but also for other cancers, including breast and renal cell carci-
noma. However, these results differ from the majority of previ-
ous studies that have shown WBC DNA hypomethylation to be 
associated with cancer.6,15,20,25-27
DNA hypomethylation is believed to lead to chromosomal 
instability28 by allowing silenced areas of the genome, such as ret-
rotransposons, to become active. In contrast, our results showed 
that DNA hypermethylation in WBCs is associated with CRC 
risk. Whether it is DNA hypomethylation or hypermethylation 
that has been associated with cancer risk, the mechanism under-
lying this association between aberrant DNA methylation and 
cancer is unknown. When considering an underlying mechanism 
in the context of our findings, a previous study has observed in 
the DNA from WBCs of healthy controls and from cell lines 
that LINE-1 sequences containing double stranded DNA breaks 
have increased methylation levels around the area of the break 
when compared with samples without double strand breaks.29 
These findings demonstrate an association between DNA dam-
age and hypermethylation in WBC DNA. The association we 
have observed between WBC DNA hypermethylation and CRC 
risk may be related to an increased frequency of double stranded 
DNA breaks in cancer-affected individuals, however, further 
studies are required to test this hypothesis.
Chemotherapy is an important factor to consider when inves-
tigating DNA methylation changes, as some studies suggest that 
chemotherapy can result in increased DNA methylation.30-32 
Apart from the Alu repetitive element, our results show no signif-
icant difference in the methylation levels of cases who underwent 
























in the MUTYH gene as previously described.49 Those cases car-
rying a pathogenic mutation in a mismatch repair gene (Lynch 
Syndrome) or biallelic or compound heterozygous mutations in 
MUTYH were identified for the stratified analysis.
Primary CRC tissue from the Australasian Colorectal Cancer 
Family Registry Jeremy Jass Memorial Tissue Bank were reviewed 
by specialist GI pathologists for site, tumor grade, tumor stage, 
tumor margin, nodal involvement, presence of mucinous compo-
nent, peritumoral lymphocytes, Crohn’s-like lymphocytic reaction, 
tumor-infiltrating lymphocytes and synchronous CRC. Tumors 
from the ileo-cecal junction through the cecum, ascending colon, 
hepatic flexure, and transverse colon were grouped as right-sided 
(proximal) colon cancers (ICD-O-3 codes C180, C182, C183 and 
C184). Tumors in the splenic flexure (C185), descending (C186), 
sigmoid colon (C187) and recto-sigmoid junction (C199) were 
classified as left-sided (distal) colon cancers, with tumors in the 
rectum (C209) considered as a third distinct group.
LINE-1, Alu and Sat2 methylation detection. For each par-
ticipant, WBCs were isolated from 18 mL of whole blood treated 
with the anti-coagulant EDTA. The DNA was extracted using a 
proteinase-K digestion and a salt-ethanol precipitation method 
which has been previously described.50 DNA was suspended in 
1× TE buffer (0.01 M Tris, pH 7.4; 0.1 mM EDTA, pH 8.0) for 
quantification, then an aliquot was diluted in water to a concen-
tration of 50 ng/μL and stored at 4°C to limit freeze thawing.
Sodium bisulphite modification was performed on 1 μg of this 
DNA using the EZ-96 Methylation Gold Kit (Zymo Research, 
catalog number D5007), according to manufacturer’s instruc-
tions. Following bisulphite conversion, 15 ng of DNA was used 
in the MethyLight real-time polymerase chain reaction for each 
DNA repetitive element region tested as previously described by 
Weisenberger et al.10 and labeled as Alu-M2, LINE-1-M1 and 
Sat2-M1, with a separate Alu region (Alu-C4) being utilized as 
the reference gene.10 The primer and probe sequences, master-
mix and cycling conditions have also been previously described,10 
with amplification performed on the Corbett Rotorgene 6000 
qPCR platform (Qiagen).
A standard curve was run in triplicate for each marker using 
four 1:10 serial dilutions of Universal Methylated DNA Standard 
(Zymo Research, catalog number D5011) with 1 μg bisulphite 
converted on each 96 well plate of samples undergoing conver-
sion. The Universal Methylated DNA standard was also used 
as a calibrator (run in duplicate) for each MethyLight marker 
per run performed. A random subset of 56 DNA samples was 
tested in triplicate to assess the variation of the assay. The level 
of DNA methylation was expressed as the percentage of methyl-
ated reference (PMR), using the following formula as previously 
described:30
Statistical analysis. All statistical analyses were performed 
using Stata version 11.2 (StataCorp). The PMR values of each 
sample were obtained by calculating the above formula using 
age) between 1997 and 2001 were ascertained from the Victorian 
Cancer Registry and recruited to the Australasian Colorectal 
Cancer Family Registry (ACCFR).39 Recruitment of CRC 
affected individuals included all cases diagnosed between 18 and 
44 years of age and 50% of cases with CRC diagnosed between 
45 and 59 years of age, irrespective of family history. Cases diag-
nosed with Familial Adenomatous Polyposis were excluded from 
the study. WBC DNA was available from 588 of the 618 probands 
diagnosed with CRC (95%). Of these 588 cases, 547 had suf-
ficient DNA available for bisulphite conversion and methylation 
analysis, of which, 8 samples failed testing. The remaining 539 
cases with methylation data were included in the study. Healthy 
controls sex and age frequency matched to cases that were living 
in Victoria were randomly selected from the population using the 
Victorian Electoral Roll.
Interviews were conducted to obtain epidemiological infor-
mation, personal and family history of cancer and dietary infor-
mation using three questionnaires. Cigarette smoking status, 
alcohol consumption, body mass index (BMI) and use of medi-
cation (folic acid, aspirin and ibuprofen) used in this study were 
derived from the period two years before date of diagnosis for 
cases, or date of interview for controls. Cigarette smoking and 
alcohol consumption were categorized as current (within two 
years of date of diagnosis/interview), former (stopped before two 
years of date of diagnosis/interview) or never smokers/drinkers. 
Blood was taken at time of recruitment and is described here as 
the age at blood draw. Written informed consent was obtained 
from all cases and controls to collect a blood sample and tumor 
pathology materials (tumor blocks and diagnostic slides). This 
study was approved by the Human Research Ethics Committees 
of all participating institutions.
Molecular and pathological characterization. Colorectal 
tumors were characterized for mismatch repair deficiency using a 
ten-marker panel to assess microsatellite instability (MSI) and/or 
by immunohistochemistry for the four mismatch repair proteins 
as has been previously described.40-42 Tumors were described as 
(1) mismatch repair deficient if they showed microsatellite insta-
bility and/or loss of expression of one or more of the mismatch 
repair proteins by immunohistochemistry or (2) mismatch 
repair proficient if tumors were microsatellite stable (or low level 
of instability) or showed stable expression of all four mismatch 
repair proteins by immunohistochemistry. In addition, tumors 
demonstrating loss of the MLH1 and PMS2 proteins by immuno-
histochemistry were characterized for methylation of the MLH1 
promoter using the MethyLight assay as previously described.43,44 
The BRAF V600E mutation status was tested for in all CRCs 
using a fluorescent allele-specific PCR assay to detect the somatic 
t: a mutation at nucleotide 1799 in exon 15 of the BRAF gene as 
has been previously described.45
Cases whose CRCs demonstrated mismatch repair deficiency 
through loss of expression of one or more of the mismatch repair 
proteins by immunohistochemistry and/or showed instability in 
30% or more of the microsatellite markers underwent germline 
mutation testing (Sanger sequencing and MLPA) irrespective of 
the tumor BRAF V600E mutation status or methylation of the 
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values gave similar results. The likelihood ratio test was used 
to assess whether the associations between PMR and CRC dif-
fered by subgroup. For analyses comparing subgroups defined by 
receipt of 5-fluoruracil (5FU) treatment, cases with T-stage 1 or 4 
were excluded from the analysis as T-stage 1 cases rarely had che-
motherapy and T-stage 4 cases almost always had chemotherapy.
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each calibrator replicate from that run, then taking the average of 
those two PMR values. Baseline characteristics of case and con-
trol subjects were compared using chi-square tests or Wilcoxon 
rank-sum tests, as appropriate.
Unconditional logistic regression models were used to assess 
the association between PMR values and CRC. Models were 
adjusted for all measured potentially confounding factors: age 
at blood draw (continuous), sex, BMI (categorized into quar-
tiles), smoking status (current, former and never), alcohol drink-
ing status (current, former and never), self-reported ethnicity 
(Caucasian/not), use of folic acid, aspirin and ibuprofen two 
years before recruitment (yes, no) and family history (first-degree 
relative (FDR) or second-degree relative (SDR)) of CRC. PMR 
values of cases were categorized into four ordered groups based 
on the quartiles among the control individuals for each repeti-
tive DNA element. The association between PMR quartile and 
CRC was assessed using three separate logistic regression models. 
Tests for trend were conducted by assigning each PMR quartile 
its median value and fitting this as a linear effect. Models were 
also fit using the natural logarithm of each PMR variable as a lin-
ear effect, with odds ratios representing the association per unit 
increase of the logged PMR variable. Odds ratios (ORs) were cal-
culated with 95% confidence intervals (CIs) and two-tailed Wald 
test p-values.
A combined measure of hypermethylation across the three 
repetitive elements was assessed by counting the number of repet-
itive elements with PMR levels in the highest quartile (Q4) for 
each individual. This variable was included in a logistic regres-
sion model similar to those described previously. Linearity of the 
association between the combined hypermethylation variable 
and CRC was assessed using the likelihood ratio test.
Associations between PMR values and CRC risk were com-
pared between different subgroups of CRC using multinomial 
regression adjusted for the confounding variables given above, 
allowing the effects of age, sex and PMR to differ between sub-
groups, while restricting the effects of other confounders to be 
the same across subgroups. The natural logarithms of the PMR 
variables were fitted as linear effects. Models using grouped PMR 
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